Abstract Library

#4247 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#3891 Exceptional response to Everolimus in a pancreatic NET G3 (pNET) – How NGS can help in treatment choice

Introduction: Exceptional Responders are defined as patients who achieve complete (CR) or partial response (PR) for at least 6 months to a treatment with population PR or CR rate less than 10%, or patients with CR or PR lasting more than three times the median duration of response.

Conference:

Presenting Author: Torresan I

Authors: Torresan I, Mafficini A, Benini L, Borghesani M, Moscarda V,

Keywords: pNET, NGS, G3, everolimus, TSC2,

#3860 NGS data collection in high-grade (HG) pancreatic NENs at University Hospital of Verona

Introduction: Molecular data for G3 pancreatic neuroendocrine neoplasms (pNEN) are limited. G3 category includes well-differentiated NET G3 and NEC. The biology and clinical behaviour of NET G3 are different from NEC.

Conference:

Presenting Author: Rossi A

Authors: Rossi A, Cingarlini S, Borghesani M, Moscarda V, Torresan I,

Keywords: NGS, pNEN, G3, precision medicine,

#1720 Yttrium90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marques B

Authors: Marques B, Martins R, Gonçalves B, Sousa M, Violante L,

Keywords: neuroendocrine, yttrium radioisotopes,